Spriggs DR - Search Results

1

Time to publication of oncology trials and why some trials are never published.

Chapman PB, Liu NJ, Zhou Q, Iasonos A, Hanley S, Bosl GJ, Spriggs DR. Chapman PB, et al. Among authors: spriggs dr. PLoS One. 2017 Sep 21;12(9):e0184025. doi: 10.1371/journal.pone.0184025. eCollection 2017. PLoS One. 2017. PMID: 28934243 Free PMC article.

2

A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies.

Iasonos A, Wilton AS, Riedel ER, Seshan VE, Spriggs DR. Iasonos A, et al. Among authors: spriggs dr. Clin Trials. 2008;5(5):465-77. doi: 10.1177/1740774508096474. Clin Trials. 2008. PMID: 18827039 Free PMC article.

3

Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remission.

Iasonos A, Sabbatini P, Spriggs DR, Aghajanian CA, O'Cearbhaill RE, Hensley ML, Thaler HT. Iasonos A, et al. Among authors: spriggs dr. Int J Gynecol Cancer. 2012 Jan;22(1):63-9. doi: 10.1097/IGC.0b013e31822e29aa. Int J Gynecol Cancer. 2012. PMID: 22080877 Free PMC article.

4

Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials.

Hyman DM, Eaton AA, Gounder MM, Smith GL, Pamer EG, Hensley ML, Spriggs DR, Ivy P, Iasonos A. Hyman DM, et al. Among authors: spriggs dr. J Clin Oncol. 2014 Feb 20;32(6):519-26. doi: 10.1200/JCO.2013.49.8808. Epub 2014 Jan 13. J Clin Oncol. 2014. PMID: 24419130 Free PMC article.

5

Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials.

Hyman DM, Eaton AA, Gounder MM, Pamer EG, Pettiford J, Carvajal RD, Ivy SP, Iasonos A, Spriggs DR. Hyman DM, et al. Among authors: spriggs dr. Oncotarget. 2015 Aug 7;6(22):19316-27. doi: 10.18632/oncotarget.2909. Oncotarget. 2015. PMID: 25682870 Free PMC article. Clinical Trial.

6

Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities.

Eaton A, Iasonos A, Gounder MM, Pamer EG, Drilon A, Vulih D, Smith GL, Ivy SP, Spriggs DR, Hyman DM. Eaton A, et al. Among authors: spriggs dr. Clin Cancer Res. 2016 Feb 1;22(3):553-9. doi: 10.1158/1078-0432.CCR-15-0339. Epub 2015 Aug 31. Clin Cancer Res. 2016. PMID: 26324741 Free PMC article.

7

Measuring Toxicity in Phase I Clinical Trials--Letter.

Hyman DM, Eaton A, Ivy SP, Spriggs DR, Iasonos A. Hyman DM, et al. Among authors: spriggs dr. Clin Cancer Res. 2016 Apr 1;22(7):1828. doi: 10.1158/1078-0432.CCR-15-3043. Clin Cancer Res. 2016. PMID: 27037257 No abstract available.

8

The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials.

Iasonos A, Gounder M, Spriggs DR, Gerecitano JF, Hyman DM, Zohar S, O'Quigley J. Iasonos A, et al. Among authors: spriggs dr. Clin Cancer Res. 2012 Oct 1;18(19):5179-87. doi: 10.1158/1078-0432.CCR-12-0726. Epub 2012 Jul 23. Clin Cancer Res. 2012. PMID: 22825582 Free PMC article.

9

Reply to M. Voskoboynik et al.

Hyman DM, Eaton AA, Gounder MM, Ivy SP, Iasonos A, Spriggs DR. Hyman DM, et al. Among authors: spriggs dr. J Clin Oncol. 2014 Oct 1;32(28):3199-200. doi: 10.1200/JCO.2014.56.5762. Epub 2014 Jul 28. J Clin Oncol. 2014. PMID: 25071117 No abstract available.

10

Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.

Drilon A, Eaton AA, Schindler K, Gounder MM, Spriggs DR, Harris P, Ivy SP, Iasonos A, Lacouture ME, Hyman DM. Drilon A, et al. Among authors: spriggs dr. Cancer. 2016 Apr 15;122(8):1228-37. doi: 10.1002/cncr.29918. Epub 2016 Feb 24. Cancer. 2016. PMID: 26916138 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

278 results

Search Page